Abstract
The health care industry today is undergoing radical changes in its economic architecture. Spiraling costs have prompted a widespread movement to reform the health care delivery system. In addition to legislative reform, there are significant market forces driving this process. Increasingly, the industry has shifted to a managed care model and a prospective payment system. Declining revenues have impelled hospitals to seek greater cost-effectiveness.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wallace EL. Costing blood products and services (editorial). Transfusion 1991;31:293–295.
Wallace EL, Wallace MA. Hospital Transfusion Charges and Community Blood Center Costs, Prepared Under Contract with the National Heart, Lung, and Blood Institute Bethesda, MD: NHLBI, 1982.
Cumming PD, Wallace EL, Surgenor DM, et al. Public interest pricing of blood services. Med Care 1974;12:743–753.
Zuck TF. An hypothesis on the cost effectiveness of homologous blood transfusions in 1988. Transfus Med Rev 1988;2:245–249.
Forbes JM, Anderson MD, Anderson GF, et al. Blood transfusion costs: a multicenter study. Transfusion 1991;31:318–323.
Lubarsky DA, Hahn C, Bennett D, et al. The hospital cost (fiscal year 1991/1992) of a simple perioperative allogeneic red blood cell transfusion during elective surgery at Duke University. Anesth Analg 1994;79:629–637.
New York Blood Center Fee Schedule. New York, NY, 1993.
Birkmeyer JD, Goodnough LT, AuBuchon JP, et al. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993;33:544–551.
Scott WJ, Rode R, Castlemain B, et al. Efficacy, complications, and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg 1992;103:1001–1007.
Baele PL, Ruiz-Gomez J, Londot C, et al. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesth Belg 1992;43:103–112.
Stevens ME, Summerfield GP, Hall AA, et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. Br Med J 1992;304:474–477.
Sheingold SH, Churchill DN, Muirhead N, Laupacis A. Recombinant human erythropoietin: factors to consider in cost-benefit analysis (editorial). Am J Kidney Dis 1991;17:86–92.
Hayashi J, Kumon K, Takanashi S, et al. Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: a double-blind, multicenter trial in Japan. Transfusion 1994;34:142–146.
Strauss RG. Can the cost of erythropoietin for cardiac surgery patients be justified? (letter). Transfusion 1994;34:835.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag
About this chapter
Cite this chapter
Krieger, K.H., Isom, O.W., Velasco, F.T. (1998). Economics of Transfusion Medicine and Blood Conservation Practices. In: Krieger, K.H., Isom, O.W. (eds) Blood Conservation in Cardiac Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2180-7_26
Download citation
DOI: https://doi.org/10.1007/978-1-4612-2180-7_26
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-94908-6
Online ISBN: 978-1-4612-2180-7
eBook Packages: Springer Book Archive